Literature DB >> 34409465

Chronic thromboembolic pulmonary hypertension: a review.

Cheryl Zhiya Chong1, Edgar Lik Wui Tay1, Ching Hui Sia1, Kian Keong Poh1.   

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a unique form of pulmonary hypertension resulting from obstruction of the pulmonary artery by fibrotic thromboembolic material, usually initiated by recurrent or incomplete resolution of pulmonary embolism. This distinct form of pulmonary hypertension is classified under Group 4 of the World Health Organization classification. Further investigations are usually initiated, with transthoracic echocardiography followed by right heart catheterisation and pulmonary angiography as the gold standard. Definitive treatment is usually in the form of surgical pulmonary endarterectomy. Inoperable CTEPH is medically treated with pharmacological agents such as phosphodiesterase Type 5 inhibitors, endothelin receptor antagonists, soluble guanylate cyclase stimulators and prostacyclin. Recent developments have made balloon pulmonary angioplasty a viable option as well. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  chronic thromboembolic pulmonary hypertension; pulmonary embolism; pulmonary endarterectomy; pulmonary hypertension; thromboemboli

Mesh:

Year:  2021        PMID: 34409465      PMCID: PMC8801849          DOI: 10.11622/smedj.2021089

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  57 in total

1.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).

Authors:  Gérald Simonneau; Andrea M D'Armini; Hossein-Ardeschir Ghofrani; Friedrich Grimminger; Marius M Hoeper; Pavel Jansa; Nick H Kim; Chen Wang; Martin R Wilkins; Arno Fritsch; Neil Davie; Pablo Colorado; Eckhard Mayer
Journal:  Eur Respir J       Date:  2014-11-13       Impact factor: 16.671

2.  Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.

Authors:  Hossein-Ardeschir Ghofrani; Gérald Simonneau; Andrea M D'Armini; Peter Fedullo; Luke S Howard; Xavier Jaïs; David P Jenkins; Zhi-Cheng Jing; Michael M Madani; Nicolas Martin; Eckhard Mayer; Kelly Papadakis; Dominik Richard; Nick H Kim
Journal:  Lancet Respir Med       Date:  2017-09-11       Impact factor: 30.700

Review 3.  Update on pulmonary arterial hypertension pharmacotherapy.

Authors:  Arash Velayati; Marcos G Valerio; Michael Shen; Sohaib Tariq; Gregg M Lanier; Wilbert S Aronow
Journal:  Postgrad Med       Date:  2016-06       Impact factor: 3.840

4.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Andrea M D'Armini; Friedrich Grimminger; Marius M Hoeper; Pavel Jansa; Nick H Kim; Eckhard Mayer; Gerald Simonneau; Martin R Wilkins; Arno Fritsch; Dieter Neuser; Gerrit Weimann; Chen Wang
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

5.  Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics.

Authors:  Szymon Darocha; Marta Banaszkiewicz; Arkadiusz Pietrasik; Michał Piłka; Michał Florczyk; Maria Wieteska; Anna Dobosiewicz; Sebastian Szmit; Adam Torbicki; Marcin Kurzyna
Journal:  Int J Cardiol       Date:  2018-07-03       Impact factor: 4.164

Review 6.  New interventions to treat chronic thromboembolic pulmonary hypertension.

Authors:  David Jenkins
Journal:  Heart       Date:  2018-04-10       Impact factor: 5.994

7.  Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension.

Authors:  Francisca Alexandra Gavilanes-Oleas; Jose Leonidas Alves; Caio Julio Cesar Fernandes; Luis Felipe Lopes Prada; William Salibe Filho; Mario Terra Filho; Luciana Morinaga; Susana Hoette; Carlos Jardim; Rogerio Souza
Journal:  Clinics (Sao Paulo)       Date:  2018-05-17       Impact factor: 2.365

8.  Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications.

Authors:  Tatsuo Aoki; Koichiro Sugimura; Shunsuke Tatebe; Masanobu Miura; Saori Yamamoto; Nobuhiro Yaoita; Hideaki Suzuki; Haruka Sato; Katsuya Kozu; Ryo Konno; Satoshi Miyata; Kotaro Nochioka; Kimio Satoh; Hiroaki Shimokawa
Journal:  Eur Heart J       Date:  2017-11-07       Impact factor: 29.983

9.  Evaluation of patients with chronic thromboembolic pulmonary hypertension for pulmonary endarterectomy.

Authors:  William R Auger; Kim M Kerr; Nick H Kim; Peter F Fedullo
Journal:  Pulm Circ       Date:  2012 Apr-Jun       Impact factor: 3.017

Review 10.  Balloon Pulmonary Angioplasty: A Treatment Option for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Aiko Ogawa; Hiromi Matsubara
Journal:  Front Cardiovasc Med       Date:  2015-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.